

## ASX RELEASE

### Volpara Quarterly Results and Investor Conference Call

Wellington, NZ, 18 October 2019: [Volpara Health Technologies](#) ("Volpara"; ASX: VHT), a medical technology company whose AI imaging algorithms assist the early detection of breast cancer, is pleased to advise it will release its Appendix 4C – Quarterly Cash Flow Statement for the period ended 30 September 2019 (Q2 FY20) on Tuesday the 22<sup>nd</sup> of October 2019.

Investors are invited to join a conference call hosted by CEO Dr Ralph Highnam, CFO Craig Hadfield and CCO, Mark Koeniguer, at 08:30am AEDT (10:30am NZST) 22 October 2019.

To pre-register, please follow this link:

<https://s1.c-conf.com/diamondpass/volpara-10002332invite.html>

*You will receive a calendar notification with dial-in details and a PIN for fast-track access to the call.*

**ENDS**

#### For further information, please contact:

Ralph Highnam, CEO  
Volpara Health Technologies  
[ralph.highnam@volparasolutions.com](mailto:ralph.highnam@volparasolutions.com)  
t: +64 21 149 0541

Trevor Chappell  
WE Buchan  
[tchappell@we-buchan.com](mailto:tchappell@we-buchan.com)  
t: +61 3 9866 1215

#### ABOUT VOLPARA HEALTH TECHNOLOGIES LIMITED (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical applications for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$95 million, including A\$55 million in June 2019. VHT is based in Wellington, New Zealand.

For more information, visit [www.volparasolutions.com](http://www.volparasolutions.com).